ADH-1, an N-cadherin antagonist, inhibits N-cadherin mediated cell adhesion.
CAT No: HB00096
CAS No:229971-81-7
Synonyms/Alias:Exherin;229971-81-7;ADH-1;ADH 1;Exherin free base;Cys-his-ala-val-cys;B058ME29VU;NSC-729477;DTXSID4044036;229971-81-7 (free base);L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-l-alanyl-L-valyl-, cyclic (1-5)-disulfide;NSC 729477;(4R,7S,10S,13S,16R)-13-((1H-imidazol-5-yl)methyl)-16-acetamido-7-isopropyl-10-methyl-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetraazacycloheptadecane-4-carboxamide;(4R,7S,10S,13S,16R)-16-acetamido-13-(1H-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide;UNII-B058ME29VU;ADH-1 pepide;CHEMBL3818130;SCHEMBL13857500;DTXCID401012044;EX-A3549;ADH-10001;AKOS030526741;CS-3450;DA-63339;HY-13541;D83667;Q4651113;BRD-K81795818-019-01-4;C518575000;
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.